Impact of varying lung function thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis

<bold>Objectives:</bold> Patient expectations can be low in progressive diseases such as COPD so achieving disease stability (DS) should be considered important; lung function is one example of a practicable DS measure. A ≥100mL change in lung function may be beneficial, however individual benefits may occur below this threshold. This analysis of IMPACT assessed the likelihood of achieving stabilisation of lung function as a measure of DS, according to different thresholds. <bold>Methods:</bold> IMPACT compared FF/UMEC/VI 100/62.5/25µg (n=4151) vs FF/VI 100/25µg (n=4134) and UMEC/VI 62.5/25µg (n=2070). Lung function was assessed as a DS measure, exploring ≥100mL improvement from baseline (pre-specified), and ≥0mL improvement/no change from baseline (CFB) (post hoc) thresholds in trough FEV₁. FF/UMEC/VI was compared vs FF/VI or UMEC/VI at Weeks 4, 16, 28, 40 and 52. <bold>Results:</bold> Patients receiving FF/UMEC/VI had significantly greater odds of achieving lung function stabilisation at either threshold (≥100mL or ≥0mL in trough FEV₁) vs FF/VI or UMEC/VI, at all time points (Week 52: <bold>Figure</bold>). <bold>Conclusion:</bold> FF/UMEC/VI resulted in a greater proportion of patients with lung function benefits over dual therapy even below ≥100mL CFB in trough FEV₁, supporting different thresholds in DS outcomes. Further analyses are needed to evaluate DS as a management goal and validate lung function as a measure of DS. <bold>Funding:</bold> GSK (CTT116855/<ext-link>NCT02164513</ext-link>) <fig><object-id>erj;64/suppl_68/OA4653/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>